Health economics-introduction

Important terms

• Base-case analysis:
• Quality-adjusted life years (QALYs): life year \(\times\) health utility weight??
• Efficacy and effectiveness: the extent to which an intervention can achieve desired outcome in ideal situation and in reality.
  
  

Values of cost-effectiveness analysis

• Provide data for reimbursement decisions
• Inform treatment guidelines
• Provide pricing benchmark
• Guide subsequent research
  
  

Reference:
1. Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes. (4th ed.) Oxford University Press.
2. Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. JAMA Neurol. 2022 May 1;79(5):478-487.
3. Cliff ERS, Kelkar AH. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease-Estimating the True Value. JAMA Neurol. 2022 Oct 3.
4. Mattke S. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease-Estimating the True Value. JAMA Neurol. 2022 Oct 3.
5. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022 Jan;25(1):3-9.